Correction to: European Journal of Clinical Microbiology & Infectious Diseases

https://doi.org/10.1007/s10096-021-04285-4

In the originally published version of the article, captions of Figures 1, 2, 3, 4, and 5 have missing figure denominations. The figures are presented here with correct captions.

Fig. 1
figure 1

Categorical results of antibody indices against time after the onset of symptoms from the COVID-19 group. Black bars, light gray bars, or dark gray bars indicate a negative, equivocal, or positive test result, respectively. a) Vircell-IgM/A b) Euroimmun-IgA c) Vircell-IgG d) Euroimmun-IgG

Fig. 2
figure 2

Box-plots of anti-SARS-CoV-2 antibody indices against time after the onset of symptoms from the COVID-19 group. The red dotted line indicates the lower manufacturer’s cutoff value (equivocal results are rated as positive results). Circles and stars depict outliers and extreme outliers, respectively. a) Vircell-IgM/A b) Euroimmun-IgA c) Vircell-IgG d) Euroimmun-IgG

Fig. 3
figure 3

Box-plots of anti-SARS-CoV-2 antibody indices against disease severity from the COVID-19 group. The red dotted line indicates the lower manufacturer’s cutoff value (equivocal results are rated as positive results). Circles and stars depict outliers and extreme outliers, respectively. a) Vircell-IgM/A b) Euroimmun-IgA c) Vircell-IgG d) Euroimmun-IgG

Fig. 4
figure 4

Box-plots of anti-SARS-CoV-2 antibody indices from the bacterial infection group and the control group. The red dotted line indicates the lower manufacturer’s cutoff value (equivocal results are rated positive results). Circles and stars depict outliers and extreme outliers, respectively. a) Vircell-IgM/A b) Euroimmun-IgA c) Vircell-IgG d) Euroimmun-IgG

Fig. 5
figure 5

Box-plots of anti-SARS-CoV-2 antibody indices from the viral infection group and the control group. The red dotted line indicates the lower manufacturer’s cutoff value (equivocal results are rated positive results). Circles and stars depict outliers and extreme outliers, respectively. a) Vircell-IgM/A b) Euroimmun-IgA c) Vircell-IgG d) Euroimmun-IgG

Layout adjustments are also made to Tables 2-5 for readability.

The original article has been corrected.